Tag: global pdr market

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Proliferative Diabetic Retinopathy (PDR) Market Size Changed, over the years?

The market size for proliferative diabetic retinopathy (PDR) has seen a swift expansion in recent years. The market, which is projected to rise from $2.42 billion in 2024 to $2.7 billion in 2025, boasts a compound annual growth rate (CAGR) of 11.6%. This growth during the historical period is linked to an increase in diabetes incidence, alterations in lifestyle habits and consumption of unhealthy diets, governmental efforts, and a higher count of vision loss related to diabetes.

How Much Will the Proliferative Diabetic Retinopathy (PDR) Market Be Worth in 2029?

The market size for proliferative diabetic retinopathy (PDR) is anticipated to witness swift expansion in the upcoming years, reaching a valuation of $4.02 billion in 2029 with a compound annual growth rate (CAGR) of 10.5%. Factors contributing to growth during that forecasted period encompass an aging populace, increased awareness and education related to diabetes, funding for research and development, and a higher demand for combination therapies. Foreseen trends over this period comprise improvements in diagnostic technologies, development in treatment alternatives, the integration of artificial intelligence (AI) for early diagnosis, advancements in gene therapy, and progressive retinal imaging.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

Which is the Largest Company in the Proliferative Diabetic Retinopathy (PDR) Market?

Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

What Are the Main Market Drivers in the Proliferative Diabetic Retinopathy (PDR) Industry?

The increase in diabetes cases is anticipated to fuel the proliferative diabetic retinopathy (PDR) market’s growth in the future. Diabetes, a long-term medical condition, results in high levels of glucose (sugar) in the blood. Diabetes is the main contributing factor to proliferative diabetic retinopathy disease. There are several treatment strategies to stop further retinal damage and maintain eyesight in people with this condition. For instance, data from the National Health Service (NHS), a UK government agency, revealed that the number of diabetes cases in individuals under 40 grew from 173,166 in 2022 to 216,440 in 2023 as of June 2024. This considerable increase shows a worrying pattern among younger age groups. The given data illustrates the swift increase in diabetes among the younger generation. Thus, the proliferative diabetic retinopathy (PDR) market is being propelled by the increasing prevalence of diabetes.

Key Market Driver for the Proliferative Diabetic Retinopathy (PDR) Market – The Effect of Obesity on Market Expansion

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp

How Is the Proliferative Diabetic Retinopathy (PDR) Market Segments Structured?

The proliferative diabetic retinopathy (PDR) market covered in this report is segmented –

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy

2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations

3) By Application: Hospitals, Clinics, Other Applications

Subsegments:

1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab

2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide

3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation

4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

What Strategic Trends Are Transforming the Proliferative Diabetic Retinopathy (PDR) Market?

The primary entities in the proliferative diabetic retinopathy market are diligently working on the innovation of new therapies aimed at boosting the efficacy of treatments, minimizing the treatment workload and enhancing patient results. For illustration, Biogen, a biotechnology company based in the US, and Samsung Bioepis, a South Korean biotech firm, launched Byooviz (ranibizumab-nuna), the USA’s premier ophthalmology biosimilar, in June 2022. These developed products are designated for the treatment of individuals suffering from diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Which Global Regions Offer the Highest Growth in the Proliferative Diabetic Retinopathy (PDR) Market?

North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

This Report Delivers Insight On:

1. How big is the proliferative diabetic retinopathy (pdr) market, and how is it changing globally?

2. Who are the major companies in the proliferative diabetic retinopathy (pdr) market, and how are they performing?

3. What are the key opportunities and risks in the proliferative diabetic retinopathy (pdr) market right now?

4. Which products or customer segments are growing the most in the proliferative diabetic retinopathy (pdr) market?

5. What factors are helping or slowing down the growth of the proliferative diabetic retinopathy (pdr) market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the proliferative diabetic retinopathy (pdr) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Proliferative Diabetic Retinopathy (PDR) Market In 2029?

The market size for proliferative diabetic retinopathy (PDR) has experienced rapid expansion in the past few years. It is forecasted to escalate from $2.42 billion in 2024 to a remarkable $2.7 billion in 2025, this corresponds to a compound annual growth rate (CAGR) of 11.6%. The aforementioned growth during the previous period can be traced back to factors such as an increasing prevalence of diabetes, alterations in lifestyle and consumption of unhealthy foods, government led initiatives, and a rise in the number of vision loss incidents related to diabetes.

The market size for proliferative diabetic retinopathy (PDR) is projected to witness speedy expansion in the years to come. The market is expected to surge to $4.02 billion by 2029, with a compound annual growth rate (CAGR) of 10.5%. This significant development in the estimated period can be credited to factors such as an increasing elderly population, heightened public cognizance and learning about diabetes, funds for research and development, and a surge in the demand for combination treatments. Characteristic trends in the projected period encompass advancements in diagnostic technology, novel treatment options, the application of artificial intelligence (AI) for early diagnosis, progress in gene therapy, and cutting-edge retinal imaging.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Proliferative Diabetic Retinopathy (PDR) Market?

The proliferative diabetic retinopathy (PDR) market is expected to surge as diabetes becomes more rampant. Diabetes, a chronic condition marked by high blood glucose levels, is the predominant cause of proliferative diabetic retinopathy, a disease manageable by various treatments aimed at preserving eyesight and averting further retinal damage. Notably, the National Health Service (NHS) in the UK disclosed in June 2024 that there has been a substantial increase in diabetes instances among individuals below 40 years – with figures rising from 173,166 in 2022 to 216,440 in 2023. This spike underscores a worrisome trend within this demographic, as it evidences a quick uptick in diabetes cases among younger people. Consequently, the escalating prevalence of diabetes acts as a primary driver for the PDR market.

Proliferative Diabetic Retinopathy (PDR) Market Driver: Impact Of Obesity On Proliferative Diabetic Retinopathy (PDR) Market Growth

 

Which Key Market Segments Comprise the Proliferative Diabetic Retinopathy (PDR) Market and Drive Its Revenue Growth?

The proliferative diabetic retinopathy (PDR) market covered in this report is segmented –

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy

2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations

3) By Application: Hospitals, Clinics, Other Applications

Subsegments:

1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab

2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide

3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation

4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp

Which Areas Are Leading Regions in the Proliferative Diabetic Retinopathy (PDR) Market Expansion Across the Globe?

North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Key Market Trends in theProliferative Diabetic Retinopathy (PDR) Market Over the Coming Years?

In an effort to bolster treatment effectiveness, lessen treatment stress, and better patient results, primary businesses operating in the proliferative diabetic retinopathy market are dedicated to developing novel therapies continuously. For instance, in June 2022, Biogen, an American biotechnology firm, and Samsung Bioepis, a biotechnology company from South Korea, launched Byooviz (ranibizumab-nuna), marking it as the first ophthalmology biosimilar in the United States. These innovations aim to aid patients diagnosed with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization.

View the full report here:

https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

How Is the Proliferative Diabetic Retinopathy (PDR) Market Conceptually Defined?

Proliferative diabetic retinopathy (PDR) refers to an advanced stage of diabetic eye disease characterized by the growth of abnormal blood vessels in the retina due to prolonged high blood sugar levels. These vessels can lead to retinal bleeding, scarring and vision impairment if left untreated, making regular eye examinations crucial for early detection and management.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Proliferative Diabetic Retinopathy (PDR) Market?

The proliferative diabetic retinopathy (PDR) market is projected to grow due to the increasing rates of diabetes. Diabetes, a chronic disease marked by high blood sugar levels, is the primary cause of proliferative diabetic retinopathy. There are several treatment options available to prevent further damage to the retina and maintain visual health. For example, data from the National Health Service (NHS) indicates a rise in diabetes cases amongst individuals under 40, from 173,166 in 2022 to 216,440 in 2023. This sharp increase underscores an alarming trend in this age demographic and reveals a quick rise in diabetes amongst the younger population. Hence, the increasing incidence of diabetes propels the proliferative diabetic retinopathy (PDR) market. The Proliferative Diabetic Retinopathy (PDR) Market is likely to see more expansion due to the growing prevalence of obesity. Obesity, a complex and chronic condition associated with excessive body fat, often leads to poor health. It is linked to insulin resistance, chronic low-grade inflammation, and increased oxidative stress, which can harm the retinal microvasculature and lead to diabetic retinopathy. As per a 2022 report by Trust for America’s Health, a US-based non-profit organization, obesity rates in the US are rising, with 40% of American adults being obese. This marks an increase from last year, as adult obesity rates have soared above 35% in 19 states, up from 16 states the previous year. Therefore, the increasing rates of obesity contribute substantially to the growth of the proliferative diabetic retinopathy (PDR) market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12911&type=smp

#What is the Anticipated CAGR of theProliferative Diabetic Retinopathy (PDR) Market, and What Factors Will Drive It?

The market size for proliferative diabetic retinopathy (PDR) has seen a swift increase in the recent past. It is projected to expand from $2.42 billion in 2024 to $2.7 billion in 2025, showing a compound annual growth rate (CAGR) of 11.6%. The increase during the historic period may be due to the rising occurrence of diabetes, alterations in lifestyle and unhealthy dietary habits, state policies, and a growing incidence of vision loss related to diabetes.

The market for proliferative diabetic retinopathy (PDR) is predicted to experience significant expansion in the upcoming years, with an anticipated value of $4.02 billion in 2029, representing a compound annual growth rate (CAGR) of 10.5%. Factors influencing this anticipated growth during the projected period include an aging demographic, heightened public comprehension and awareness about diabetes, funds dedicated to research and development, and increasing requirement for combined therapies. Notable trends for the projected period comprise advancements in diagnostic technologies, innovative treatment options, the use of artificial intelligence (AI) for prompt diagnosis, advancements in gene therapy, and sophisticated retinal imaging.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12911

What Are the Key Market Innovations in theProliferative Diabetic Retinopathy (PDR) Market Over the Coming Years?

Top organizations involved in the proliferative diabetic retinopathy market consistently emphasize on the development of unique therapies to escalate the efficiency of treatment, decrease the hardship of treatment and augment patient results. For instance, Biogen, an American biotechnology firm, in collaboration with Samsung Bioepis, a biotech firm from South Korea, launched Byooviz (ranibizumab-nuna) in the United States, making it the first ophthalmology biosimilar in the country, in June 2022. These products are applied in the treatment of individuals suffering from diabetic macular edema, proliferative diabetic retinopathy, wet AMD (neovascular age-related macular degeneration), and choroidal neovascularization.

Who Are the Top Companies Driving Innovation and Growth in theProliferative Diabetic Retinopathy (PDR) Market?

Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/proliferative-diabetic-retinopathy-pdr-global-market-report

Which Key Market Segments Comprise the Proliferative Diabetic Retinopathy (PDR) Market and Drive Its Revenue Growth?

The proliferative diabetic retinopathy (PDR) market covered in this report is segmented –

1) By Treatment Type: Anti-VEGF (Vascular Endothelial Growth Factor) Therapy, Intraocular Steroids, Laser Surgery, Vitrectomy

2) By Mode of Administration: Injectables, Oral, Other Mode Of Administrations

3) By Application: Hospitals, Clinics, Other Applications

Subsegments:

1) By Anti-VEGF Therapy: Aflibercept, Ranibizumab, Bevacizumab

2) By Intraocular Steroids: Triamcinolone Acetonide, Dexamethasone Implant, Fluocinolone Acetonide

3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Laser Photocoagulation

4) By Vitrectomy: Pars Plana Vitrectomy, Anterior Vitrectomy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=12911&type=smp

Which Regions Are Emerging as Leaders in the Proliferative Diabetic Retinopathy (PDR) Market?

North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Reports Similar to the Global Proliferative Diabetic Retinopathy (PDR) Market 2025, By The Business Research Company:

Pet Diabetes Care Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/pet-diabetes-care-devices-global-market-report

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Smart Insulin Pens Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: